New hope for lupus skin flares? drug shows promise in early trial
NCT ID NCT03288324
First seen Mar 05, 2026 · Last updated Jun 15, 2026 · Updated 16 times
Summary
This study tested the drug tofacitinib in 13 young adults aged 18 to 45 with moderate to severe lupus skin disease. The goal was to see if the drug is safe and can reduce skin symptoms. Participants took the drug for up to 76 weeks, and doctors measured how well it worked using a skin severity score.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
MetroHealth Medical Center
Cleveland, Ohio, 44109, United States
Conditions
Explore the condition pages connected to this study.